Eaton Vance Management’s BridgeBio Pharma BBIO Stock Holding History

Eaton Vance Management’s Portfolio BBIO Stock Details BBIO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	–	Sell	-43,845	Closed	-$445K	–	1591
2022 Q1	$445K	Buy	+43,845	New	+$450K	﹤0.01%	1544
2021 Q4	–	Sell	-487	Closed	–	–	2814
2021 Q3	$0	Buy	+487	New	+$26.1K	﹤0.01%	2052
2021 Q2	–	Sell	-5	Closed	–	–	2820
2021 Q1	$0	Buy	+5	New	+$327	﹤0.01%	2884

Other funds holding BBIO

KKRC

Kohlberg Kravis Roberts & Co New York $5.35B AUM 63.01% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

ACM

Aisling Capital Management New York $476M AUM 128.63% 1-Year Est. Return

HHLR Advisors Grand Cayman, Cayman Islands $1.67B AUM 7.53% 1-Year Est. Return

AIG

American International Group New York $609M AUM 23.67% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Eaton Vance Management's BBIO Position: Q2 2022 in Review

Eaton Vance Management sold out of BridgeBio Pharma (BBIO) in Q2 2022, closing a stake of 43,845 shares — an estimated $445K sold.

Eaton Vance Management first reported a position in BBIO in Q1 2021 and held it in 3 quarters. The position peaked at $445K in Q1 2022. 164 funds tracked by Wall St. Rank hold BBIO as of Q2 2022.

Eaton Vance Management reported no remaining BridgeBio Pharma position as of Q2 2022 after selling out during the quarter.
Eaton Vance Management sold 43,845 BridgeBio Pharma shares in Q2 2022, an estimated $445K.
Eaton Vance Management first reported a position in BridgeBio Pharma in Q1 2021 and held it in 3 quarters.
Eaton Vance Management's BridgeBio Pharma position peaked at $445K in Q1 2022.
164 funds tracked by Wall St. Rank held BridgeBio Pharma as of Q2 2022.

Based on Eaton Vance Management's 13F filing for Q2 2022, filed 15 Aug 2022.